Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 268

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 268
---
 invested or otherwise used by directors for our benefit until they are claimed. A dividend
or other money remaining unclaimed 12 years after it first became due for payment will be forfeited and shall revert to the Company.

A shareholder’s right
to receive dividends on his shares may, if they represent more than 0.25% of the issued shares of that class, be suspended by the directors
if he fails to comply with a proper request for the disclosure of interests regarding the shares. See “Other United Kingdom Law Considerations—Disclosure of Interests in Shares” in this prospectus.

Change of Control

There is no specific provision
in our Articles of Association that would have the effect of delaying, deferring or preventing a change of control. We are, however, subject
to the provisions of the City Code, which contains detailed provisions regulating the timing and manner of any takeover offer for those
of the Company’s shares which confer voting rights. See “Other United Kingdom Law Considerations—City Code on Takeovers and Mergers” in this prospectus.

| 132 |

Variation of Rights

Whenever our share capital
is divided into different classes of shares, all or any of the rights attached to any class may be varied or abrogated in such manner
(if any) as may be provided by those rights or (in the absence of any such provision) either with the consent in writing of the holders
of at least 75% of the issued shares of that class or with the authority of a special resolution passed at a separate general meeting
of the holders of the shares of that class.

Alteration of Share Capital and Repurchases

Subject to the provisions
of the Companies Act, and without prejudice to any relevant special rights attached to any class of shares, we may, from time to time:

| · | increase our share capital by allotting and issuing new shares in accordance with the our articles of 
 association and any relevant shareholder resolution;                                                  |

| · | consolidate all or any of our share capital into shares of a larger nominal amount (i.e., par value) than 
 the existing shares;                                                                                      |

| · | subdivide any of our shares into shares of a smaller nominal amount (i.e., par value) than our existing 
 shares; or                                                                                              |

| · | redenominate our share capital or any class of share capital. |

Preemptive Rights and New Issuance of Shares

Under the Companies Act, the
issuance of equity securities (